Home>Topics>Stocks>Teva Pharmaceutical Industries

Teva Pharmaceutical Industries TEVA

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. ETF Reports
  7. Headlines
    1. Kindred 30.33% Upside Paced Healthcare August Dividend Dogs


      Mon, 18 Aug 2014

      By Fredrik Arnold : Results from here , as verified using Yahoo Finance data for small, mid, & large cap healthcare sector stocks, as of market closing prices August 15 compared with analyst mean target price results one year hence showed Kindred Healthcare, Inc. (NYSE: KND ), flaunted a 30.33% ...

    2. BRIEF-Active Biotech's partner Teva initiates trial in Huntington's disease


      Thu, 14 Aug 2014

      Aug 14 (Reuters) - Active Biotech : * Active biotech's partner teva initiates a laquinimod clinical trial in

    3. New Morningstar Analyst Report for Cubist Pharmaceuticals Inc

      Stock Reports

      Wed, 13 Aug 2014

      Cubist acquired Adolor Corp. in 2011 and Calixa Therapeutics in 2010. Teva had challenged Cubicin's patents, but the two firms reached a licensing agreement that will enable Teva to sell generic Cubicin in early 2018. This news was a big win for

    4. Appleseed Letter to Shareholders


      Tue, 12 Aug 2014

      PAGEBREAK> At the current time, the Appleseed Fund’s equity portfolio owns healthcare stocks such as Teva Pharmaceuticals ( TEVA ), Novartis (NVS), and PDI Inc. (PDII) due in part to our view that healthcare will continue to grow faster

    5. New Morningstar Analyst Report for Actavis PLC

      Stock Reports

      Fri, 8 Aug 2014

      Actavis Standard marks for shareholder stewardship. Historically, Actavis has avoided an aggressive acquisition strategy like Teva and Mylan, but management has proved adept at finding niche generic opportunities, including Lipitor, Lovenox, and Concerta

    6. Mylan Will Likely Need Key Product Approvals to Meet Uncertain Year-End Outlook


      Thu, 7 Aug 2014

      outlook of $3.25 to $3.45 due to our estimate of an ongoing delay in key product launches, particularly a generic version of Teva ’s Copaxone. We have made no major changes to our longer-term forecast, including the integration of Abbott’s non

    7. Mylan: Buy, Sell, Or Hold


      Tue, 5 Aug 2014

      The company's stock has handily outperformed the S&P 500 over the last five years and has crushed one of its peers (NYSE: TEVA ) in that time while underperforming Actavis (NYSE: ACT ) in that time. MYL Total Return Price data by YCharts In this article

    8. New Morningstar Analyst Report for Akorn Inc

      Stock Reports

      Tue, 5 Aug 2014

      very attractive takeover candidate, but we do not incorporate a takeover premium into our valuation. Large generic firms ( Teva , Actavis, Mylan) have repeatedly expressed interest in acquisitions and a desire to grow their presence in difficult-to

    9. Momenta Pharmaceuticals Heading For A Repeat


      Tue, 5 Aug 2014

      By Cory Renauer : While most promising young biotechs devote all resources to development of new drugs, Momenta Pharmaceuticals (NASDAQ: MNTA ) is adopting a fairly unusual strategy of aiming for the middle. Its plan for developing biosimilars -- generic versions of complex biologics -- yielded ...

    10. 2nd Half Of 2014 Biotechnology Catalysts-Part 3


      Mon, 4 Aug 2014

      By Alexander Maxwell : It can be very hard for investors to be able to keep track of all of the different events going on within the biotech world, with clinical trial results, and FDA decisions happening rather frequently. The purpose of this article is to hopefully make investor's lives a little

    « Prev12345Next »
    Content Partners